Publications by authors named "K Y Liaw"

Article Synopsis
  • Glioblastoma multiforme (GBM) presents a challenge for treatment due to its antigenic variability, prompting researchers to develop multivalent immunotherapies that target multiple tumor antigens to improve effectiveness.
  • The study introduces a new class of antibodies called DNA-encoded tri-specific T-cell engagers (DTriTEs) that target two specific GBM antigens and engage T cells, showing promising in vitro and in vivo results.
  • The leading DTriTE construct, DT2035, not only significantly reduced tumor burden and improved survival rates in mouse models but also showed sustained expression and induced strong immune responses, making it a potential game-changer for GBM treatment.
View Article and Find Full Text PDF

Background: Diabetes mellitus is the most challenging and fastest-growing global public health concern. Approximately 10.5% of the global adult population is affected by diabetes, and almost half of them are undiagnosed.

View Article and Find Full Text PDF

Background: Advanced clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer for which long-term survival rates are abysmal, though immunotherapies are showing potential. Not yet clinically vetted are bispecific T cell engagers (BTEs) that activate T cell-mediated cancer killing through intercellular synapsing. Multiple BTE formats exist, however, with limited cross-characterizations to help optimize new drug design.

View Article and Find Full Text PDF

Background: Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries.

Methods: The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.

View Article and Find Full Text PDF

Although randomized controlled trials (RCTs) are the gold standard for establishing the efficacy and safety of a medical treatment, real-world evidence (RWE) generated from real-world data has been vital in postapproval monitoring and is being promoted for the regulatory process of experimental therapies. An emerging source of real-world data is electronic health records (EHRs), which contain detailed information on patient care in both structured (eg, diagnosis codes) and unstructured (eg, clinical notes and images) forms. Despite the granularity of the data available in EHRs, the critical variables required to reliably assess the relationship between a treatment and clinical outcome are challenging to extract.

View Article and Find Full Text PDF